Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp (EXAS)
:EXAS
EXAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$40.62 - $79.62
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.26M
Market Cap
$8.11B
Enterprise Value$12.15B
Total Cash (Recent Filing)$600.89M
Total Debt (Recent Filing)$2.75B
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 07, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.56
Shares Outstanding185,755,400
10 Day Avg. Volume1,733,118
30 Day Avg. Volume2,264,518
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.07
Price to Cash Flow (P/CF)45.00
P/FCF Ratio40.80
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.33
Enterprise Value/Ebitda-15.19
Forecast
1Y Price Target
$69.50Price Target Upside59.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Exact Sciences News
See All EXAS News
---
Bulls Say, Bears Say
Bulls Say
Investment OpportunityEXAS trades at a discount compared to peers, presenting an attractive investment opportunity.
Market AdoptionCologuard Plus is expected to add approximately 2% growth, mostly during 2H 2025.
Product PerformanceCologuard Plus offers improved performance compared to the original Cologuard test, with 95% cancer sensitivity and 94% specificity.
Bears Say
Financial PerformanceLowering the 2025 revenue estimate to $3.040 billion from $3.065 billion and Adjusted EBITDA to $415 million from $541 million.
Growth ExpectationsDespite significant drivers, EXAS guided to only 11% growth for 2025 compared to their 15% 2022-27 CAGR, which is underwhelming for investors.
Operational ChallengesEXAS has to deliver beats for the shares to inflect upwards, especially after the impact from commercial sales force challenges.
---
Ownership Overview
1.07% Insiders
45.52% Mutual Funds
34.26% Other Institutional Investors
4.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAS FAQ
What was Exact Sciences Corp’s price range in the past 12 months?
Exact Sciences Corp lowest stock price was $40.62 and its highest was $79.62 in the past 12 months.
What is Exact Sciences Corp’s market cap?
Exact Sciences Corp’s market cap is $8.11B.
When is Exact Sciences Corp’s upcoming earnings report date?
Exact Sciences Corp’s upcoming earnings report date is May 07, 2025 which is in 38 days.
How were Exact Sciences Corp’s earnings last quarter?
Exact Sciences Corp released its earnings results on Feb 19, 2025. The company reported -$4.67 earnings per share for the quarter, missing the consensus estimate of -$0.307 by -$4.363.
Is Exact Sciences Corp overvalued?
According to Wall Street analysts Exact Sciences Corp’s price is currently Undervalued.
Does Exact Sciences Corp pay dividends?
Exact Sciences Corp does not currently pay dividends.
What is Exact Sciences Corp’s EPS estimate?
Exact Sciences Corp’s EPS estimate is -0.33.
How many shares outstanding does Exact Sciences Corp have?
Exact Sciences Corp has 185,755,400 shares outstanding.
What happened to Exact Sciences Corp’s price movement after its last earnings report?
Exact Sciences Corp reported an EPS of -$4.67 in its last earnings report, missing expectations of -$0.307. Following the earnings report the stock price went down -1.922%.
Which hedge fund is a major shareholder of Exact Sciences Corp?
Currently, no hedge funds are holding shares in EXAS
---
Exact Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.50 (59.18% Upside)
$69.50 (59.18% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 43.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.77%
12-Months-Change
Fundamentals
Return on Equity
-37.09%
Trailing 12-Months
Asset Growth
-10.83%
Trailing 12-Months
Company Description
Exact Sciences Corp
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
---
EXAS Company Deck
---
EXAS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant revenue and EBITDA growth, especially in the Screening segment. The company highlighted major achievements like FDA approval for Cologuard Plus and strong international expansion in Precision Oncology. However, the call also addressed challenges such as a substantial non-cash impairment charge related to the Thrive acquisition and modest growth in Precision Oncology. Overall, the positive aspects of revenue growth, new product launches, and strategic advancements outweigh the lowlights, indicating a positive sentiment.Read More>---
EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXAS Stock 12 Month Forecast
Average Price Target
$69.50
▲(59.18% Upside)
Technical Analysis
Best Analysts Covering EXAS
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+32.27%
reiterated a buy rating 6 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +32.27% per trade.
---